Category list : Combination products
Sort by: Newest first Oldest first A-Z Z-A
-
Power of one: what is holding polypills back? Subscription
Single pills with fixed-dose combinations of several medicines are not commonplace for the treatment of cardiovascular disease. As the first randomised controlled trial to show a polypill can cut the risk of heart attacks is published, we look at why, nearly two decades after it was first proposed, development and uptake is limited.
-
Combination treatment for hepatitis C approved by FDA
The US Food and Drug Administration (FDA) has approved the use of the combination treatment Vosevi (sofosbuvir, velpatasvir and voxilaprevir) for the treatment of adults with chronic hepatitis C virus (HCV) genotypes 1–6 without cirrhosis or with mild cirrhosis.
-
Modelling approach could optimise drug combination choice Subscription
Researchers used polynomial modelling to simulate complex drug-dose effects and found that they could accurately predict the dose-effect function of drug combinations.
-
COPD patients who use opioids at risk from respiratory complications
Older patients with chronic obstructive pulmonary disease who take opioids to relieve their symptoms increase their risk of dying from a respiratory-related complication compared with non-opioid users, according to new research.
-
Combination immunotherapy for advanced melanoma gets early approval from NICE
The immunotherapy combination nivolumab/ipilimumab has been recommended for patients with advanced malignant melanoma, according to draft guidance from the National Institute for Health and Care Excellence (NICE).
-
High-risk women need more frequent doses of HIV drugs Subscription
Researchers say more frequent pre-exposure prophylaxis is required to protect women from HIV.
-
Palbociclib drug combination slows advanced breast cancer Subscription
Combining the first-in-class targeted drug palbociclib with the hormone drug fulvestrant delays the progression of advanced breast cancer by an average of nine months — twice as long as when fulvestrant was given alone — a study shows.
-
Cyramza indication extended Subscription
The indication of Cyramza (ramucirumab; Eli Lilly), in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), has been extended to include the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. In addition, Cyramza in combination with docetaxel is also indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung ...
-
HIV resistance to tenofovir surprisingly common Subscription
International study finds high proportion of HIV patients were resistant to cART drug tenofovir.
-
On-demand prophylaxis protects against HIV infection in at-risk men Subscription
Randomised trial shows pre-exposure prophylaxis reduced the risk of HIV transmission by 86%.
-
Combining naproxen with other analgesics does not improve low back pain Subscription
A ten-day course of naproxen and placebo was just as effective at relieving low back pain as naproxen combined with other pain medications.
-
New hepatitis C combination treatment effective in HIV coinfected patients Subscription
Patients with both hepatitis C virus and HIV responded well to daclatasvir combined with sofosbuvir in a study.
-
Rezolsta available for HIV Subscription
Rezolsta, a darunavir 800mg and cobicistat 150mg combination tablet, is now available from Janssen for the treatment of HIV in adults. NHS list price, 30 tablets, £317.24.
Show 10 per page20 per page
